Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis

Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) is now standard first-line therapy for mNSCLC patients without sensitizing driver mutations. Anti-PD-1 and anti-PD-L1 mAbs are considered to be equivalent in efficacy. In the absence of head-to-head randomized...

Full description

Bibliographic Details
Main Authors: Joe Q. Wei, Alexander Yuile, Malinda Itchins, Benjamin Y. Kong, Bob T. Li, Nick Pavlakis, David L. Chan, Stephen J. Clarke
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Biomedicines
Subjects:
immunotherapy
chemoimmunotherapy
non-small cell lung cancer
anti-PD-1
anti-PD-L1
Online Access:https://www.mdpi.com/2227-9059/11/7/1827

Internet

https://www.mdpi.com/2227-9059/11/7/1827

Similar Items